Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Duke University |
---|---|
Information provided by: | Duke University |
ClinicalTrials.gov Identifier: | NCT00586690 |
Evaluate the safety of NK cell infusion using CD56 monoclonal antibody selected with Miltenyi Biotec system following nonmyeloablative stem cell transplantation from matched donors. This pilot study will evaluate toxicity including mortality, occurrence of acute graft versus host disease and other severe toxicity.
Condition | Intervention | Phase |
---|---|---|
Lymphoma |
Procedure: NK Cell Infusion following SCT from matched donors |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety Study |
Official Title: | Safety Trial of NK Cell Donor Lymphocyte Infusions From 6/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation |
Estimated Enrollment: | 32 |
Study Start Date: | May 2005 |
Estimated Study Completion Date: | May 2010 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
I: Experimental
NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from matched donors
|
Procedure: NK Cell Infusion following SCT from matched donors
The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
|
The use of non-selected donor lymphocyte infusions (DLIs) (to help early immune recovery and induce antitumor response) following nonmyeloablative allogeneic stem cell transplantation is also complicated by the risk of acute graft versus host disease (aGVHD) with 30-40% of patients experiencing grade III-IV aGVHD. Data suggests that the use of natural killer (NK) cells (instead of nonselected DLIs) in this setting may mediate a graft versus tumor (GVT) effect independently of aGVHD.
This pilot study is designed to evaluate the feasibility and toxicity of donor natural killer (NK) cell selection and infusion following nonmyeloablative allogeneic stem cell transplantation from matched donors. Additionally, we will assess immune reconstitution/function post NK cell infusion and evaluate efficacy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jennifer Loftis, RN, BSN, OCN | 919-668-1939 | lofti002@mc.duke.edu |
Contact: Donna Adams | 919-668-4716 | adams068@mc.duke.edu |
United States, North Carolina | |
Duke University Health System | Recruiting |
Durham, North Carolina, United States, 27710 | |
Contact: David Rizzieri, MD 919-668-1014 rizzi003@mc.duke.edu | |
Contact: Nelson Chao, MD 919-668-1011 chao0002@mc.duke.edu |
Principal Investigator: | David Rizzieri, MD | Duke University Health System |
Responsible Party: | Duke University Health System, Department of Medicine, Cell Therapy Div. ( David Rizzieri, MD ) |
Study ID Numbers: | 00005124 |
Study First Received: | December 21, 2007 |
Last Updated: | August 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00586690 |
Health Authority: | United States: Food and Drug Administration |
Stem cell transplant matched donor NK infusion |
Lymphatic Diseases Antibodies Immunoproliferative Disorders |
Lymphoproliferative Disorders Lymphoma Immunoglobulins |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |